Results 241 to 250 of about 2,398,808 (296)

Synthesis and Characterization of Biocompatible Manganese‐Doped Titania Nanoparticles and Its Application to Single‐Cell Nanoencapsulation

Advanced Materials Interfaces, EarlyView.
Biocompatible Mn‐doped TiO2 nanozymes integrate TiO2 stability with Mn redox activity, enabling dopamine‐mediated cell‐surface polymerization and single‐cell nanoencapsulation while maintaining high colloidal stability, low ROS generation, and excellent cellular compatibility.
Filip Kozłowski, Nayoung Kim, Hyunwoo Choi, Geoffrey Daniel, Gulaim A. Seisenbaeva, Insung S. Choi, Vadim G. Kessler   +6 more
wiley   +1 more source

The Evolution of Aerosol Jet Printing, A Review: Enhancing Material Versatility and Improvements for Next‐Generation Applications

Advanced Materials Technologies, EarlyView.
Aerosol Jet Printing (AJP) has emerged as a versatile additive manufacturing technique for high‐resolution, conformal, and multi‐material printing. This review highlights advances in printable materials, substrate compatibility, post‐processing, characterization, and process innovations, while critically discussing current challenges and future ...
Chandrachur Chatterjee, Rocco Lupoi, Michael J. Gibbons   +2 more
wiley   +1 more source

Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. [PDF]

Clin Cancer Res
Rampa DR, Seo M, Ogata N, Yang Z, Sridhar N, Fujii T, Wannaphut C, Maynard JA, Tsuchikama K, Sledge GW, Ueno NT, Lee J.   +11 more
europepmc   +1 more source

HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. [PDF]

Circulation
Che Y, Yamamura Y, Jung S, Sabiu G, Kondengadan SM, Lucia SE, Song Y, Byun H, Li X, Seelam AJ, Yamamura M, Inoue Y, Zhao J, Madsen JC, Kasinath V, Uchimura K, Tsokos GC, Kim P, Bromberg JS, Abdi R.   +19 more
europepmc   +1 more source

Mislocalisation of FLT3-ITD receptor contributes to MV4-11 leukaemia cell resistance to antibody-drug conjugate. [PDF]

J Enzyme Inhib Med Chem
Nirachonkul W, Farrell MP, Tolbert TJ, Okonogi S, Tima S, Anuchapreeda S, Chiampanichayakul S, Siahaan TJ.   +7 more
europepmc   +1 more source

A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma. [PDF]

NPJ Precis Oncol
Chen GL, Guo Y, Yang Y, Sang Y, Sun S, Liu X, Zhou X, Sheng CY, He X, Wang J, Shi R, Wang Y, Ji Q, Ji D.   +13 more
europepmc   +1 more source

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. [PDF]

Nat Med
Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, Dowlati A, Morgensztern D, Papadopoulos KP, Choudhury NJ, Vieito M, Bar J, Kim JH, Akerley W, Kim TM, Kim YC, Paz-Ares L, Ahn MJ, Yokouchi H, Meiman D, Munasinghe W, Ogunyankin O, Jahchan N, Wang S, Ferlini C, Robinson RR, Kohlhapp FJ, Palenski T, Rivell G, Hingorani P, Chandana S.   +30 more
europepmc   +1 more source

CD74-Targeting Antibody-Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus. [PDF]

Int J Mol Sci
Du Q, Yao S, Huang Y, Zhang J, Sonam W, Lu X, Yang J, Cheng S, Wang R, Xu J, Ma L, Liu Y, Wu G, Zhang J, Wang X, Lu W, Ling Z, Yi C, Sun B.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antibody drug conjugates

Current Opinion in Oncology, 2014
Antibody conjugates are a diverse complex class of therapeutics, consisting of a potent cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells or an extracellular target, that are having impact in the clinic.
BATT DAVID BRYANT, ETTENBERG SETH ALEXANDER, HAUBST NICOLE, HU TIANCEN, JENKINS DAVID, TOKSOZ ENGIN, PETROPOULOS KONSTANTIN, MEYER MATTHEW JOHN   +7 more
  +22 more sources

Antibody drug conjugates

Biotechnology Letters, 2016
Antibody drug conjugates (ADCs) have emerged as a viable option in targeted delivery of highly potent cytotoxic drugs in treatment of solid tumors. At the time of writing, only two ADCs have received regulatory approval with >40 others in clinical development. The first generation ADCs suffered from a lack of specificity in amino acid site-conjugations,
ABRAMS TINYA, COHEN STEVEN BRUCE, DAMIANO JASON, DÜRR CLEMENS, HUBER THOMAS, MENEZES DANIEL, MILLER KATHY, RENDAHL KATHERINE, RONDEAU JEAN-MICHEL RENE   +8 more
openaire   +7 more sources